RUSSIA LAUNCHES MASSIVE DRONE AND MISSILE BARRAGE ON UKRAINE, KILLING AT LEAST 18 CIVILIANS AND STRIKING KYIV AND MULTIPLE CITIES. (PHOTO).

Image
 Russia launches massive drone and missile barrage on Ukraine, killing at least 18 civilians and striking Kyiv and multiple cities  Russia carried out a large-scale overnight assault on Ukraine, launching hundreds of drones and dozens of missiles that killed at least 18 civilians and wounded more than 100 others across multiple cities, officials said Tuesday. The strikes hit Kyiv, Dnipro and other regions, with emergency crews working through destroyed residential buildings where some victims were trapped under rubble. In Dnipro, rescuers recovered the bodies of a 3-year-old child and a mother and her 8-year-old son, while officials reported 12 deaths in the city and six in Kyiv. The bombardment stretched from night into daylight, with explosions reported across wide areas of the country. Kyiv residents had been on alert for days after warnings of a major aerial attack, including advisories for foreign diplomats to leave the capital. Despite those warnings, most remained in pl...

GSK CEO TO RESIGN BY THE END OF THE YEAR. (PHOTO).


 GSK CEO to resign by the end of the year

GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down on Dec. 31 after more than eight years at the helm of the London-based drugmaker.

Walmsley, 56, will be succeeded by Luke Miels, currently GSK’s chief commercial officer, the company announced Monday. During her tenure, Walmsley oversaw several strategic initiatives, including the spinoff of the consumer health business Haleon, but the company’s overall performance has underwhelmed investors. GSK shares rose 3.3% to 1,534.50 pence in early trading, making it the top gainer on the London Stock Exchange.

Despite these gains, GSK’s stock has fallen 11% since Walmsley took over on April 1, 2017. Analysts say the company has delivered on financial guidance but continues to experience slow growth. Derren Nathan, head of equity research at U.K.-based Hargreaves Lansdown, noted that while GSK has achieved progress, “the share price performance has been lackluster” and growth rates remain in the single digits.

Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).